Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TP plus apatinib for platinum-sensitive recurrent ovarian cancer
ChiCTR-OIC-16009060Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Oct 2016
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in ovarian cancer, sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Progression-free survival. Planned start Oct 2016; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on ChiCTR-OIC-16009060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-16009060.